Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Temozolomide in Glioblastoma Rehabilitation
NCT03796507Phase 1Withdrawn
- Sponsor
- University of Rochester
- Start
- Sep 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of temozolomide in glioblastoma (GBM), sponsored by University of Rochester. Primary endpoint: Number of patients who fail to complete temozolomide at 1 month. Planned start Sep 2021; status: withdrawn.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03796507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03796507.